📰 "Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Potential Early Indicators of Osmotic Brain Stress in Hyponatremia and Its Correction"
https://doi.org/doi:10.1093/ejendo/lvag103https://pubmed.ncbi.nlm.nih.gov/42299484/ #Neurofilament #Gfap📰 "Biomarker Based ARIA Stress Test: A Proposed Conceptual Framework for Dynamic Biomarker-Guided ARIA Risk Stratification in Anti-Amyloid Immunotherapy for Alzheimer's Disease"
https://doi.org/doi:10.1007/s12031-026-02560-7https://pubmed.ncbi.nlm.nih.gov/42298214/ #Gfap📰 "Temporal Pattern and Clinical Value of Serum GFAP in Acute Ischemic Stroke: Results from Two Prospective German Cohorts"
https://doi.org/doi:10.1007/s12975-026-01458-1https://pubmed.ncbi.nlm.nih.gov/42295622/ #Gfap
Temporal Pattern and Clinical Value of Serum GFAP in Acute Ischemic Stroke: Results from Two Prospective German Cohorts - Translational Stroke Research
Serum glial fibrillary acidic protein (sGFAP) is an astroglial biomarker preliminarily investigated in acute ischemic stroke (AIS). We aimed to investigate its temporal pattern and clinical value in two German AIS cohorts. Using immunoassay, we measured sGFAP concentrations in 952 samples of 572 AIS patient and 32 samples of controls recruited in Halle [AIS n = 102, age: 70.9 (± 15.9) years, 52.0% males; controls n = 32, age: 47.6 (± 18.8) years, 59.4% males] and Würzburg [AIS n = 470, age 74.6 (± 12.8) years, 48.3% males]. In AIS patients, we stratified samples according to the time from symptom onset to blood sampling, namely at D1 (< 24 h), D2 (24–48 h), D3 (48–72 h) and D5-7 (96–144 h), and tested associations between biomarker levels and clinical data. sGFAP level was increased at all timepoints after AIS compared to control subjects (p < 0.001, age-adjusted p < 0.01) with significant changes over time (D1 < D2< D3 ≥ D5-7). We found increased sGFAP concentrations in AIS patients who had altered mental status on admission (p < 0.01), hemorrhagic transformation of AIS (HT, p < 0.001) as well as systemic infections such as pneumonia (p < 0.001). Higher D1 sGFAP concentrations were associated with higher likelihood of modified Rankin Scale > 2 at 3 months [aOR = 1.015 (95%CI = 1.005–1.025), p = 0.004] and a shorter survival at longest follow-up (median: 576 days, max 922 days) [highest tertile vs. lowest tertile HR = 2.94 (95%CI = 1.21–7.17), p = 0.018]. sGFAP is elevated after AIS and of informative value regarding the risk HT and infections, as well as on the clinical outcome at follow-up.
📰 "Age at onset distinguishes clinical features and relapse risk in autoimmune glial fibrillary acidic protein astrocytopathy"
https://doi.org/doi:10.3389/fimmu.2026.1856124https://pubmed.ncbi.nlm.nih.gov/42292477/ #Gfap
Frontiers | Age at onset distinguishes clinical features and relapse risk in autoimmune glial fibrillary acidic protein astrocytopathy
BackgroundAge is a critical factor influencing the clinical presentation of neuroimmunological diseases. This study aimed to investigate the different clinic...
📰 "Long-term molecular effects of 16O-ion exposure in rat brain and implications for space radiation risk"
https://doi.org/doi:10.1038/s41526-026-00622-zhttps://pubmed.ncbi.nlm.nih.gov/42285991/ #Gfap📰 "Postconcussion physical activity frequency and plasma biomarker associations among adolescents"
https://doi.org/doi:10.3171/2026.2.PEDS25624https://pubmed.ncbi.nlm.nih.gov/42284615/ #Gfap📰 "Age- and Sex-Related Differences in GFAP and UCH-L1 Levels in Mild Traumatic Brain Injury"
https://doi.org/doi:10.3390/ijms27114944https://pubmed.ncbi.nlm.nih.gov/42278473/ #Gfap📰 "Quantitative Assessment of GFAP-Based Astrocyte Morphology in the Cuprizone Model: A Comparative Evaluation of Neurolucida( ) 360 and SNT"
https://doi.org/doi:10.3390/cells15110964https://pubmed.ncbi.nlm.nih.gov/42274557/ #Gfap📰 "High-dose N-acetyl cysteine reduces GFAP levels: Exploratory results from a pilot double-blind, placebo-controlled randomized trial"
https://doi.org/doi:10.1177/13524585261454840https://pubmed.ncbi.nlm.nih.gov/42273981/ #Gfap📰 "Efgartigimod as adjunctive therapy in refractory autoimmune glial fibrillary acidic protein astrocytopathy: a case series"
https://doi.org/doi:10.1007/s00415-026-13908-9https://pubmed.ncbi.nlm.nih.gov/42268313/ #Gfap
Rxiv cytoskeleton